Rachel M. Gittelman

Rachel M. Gittelman

Auto-generated profile, based on publicly available information

Rachel M. Gittelman

Adaptive Biotechnologies, Seattle, Washington, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CBChristian U. Blank
Christian U. Blank
ERElisa A. Rozeman
Elisa A. Rozeman
LFLorenzo F. Fanchi
Lorenzo F. Fanchi
KSKarolina Sikorska
Karolina Sikorska
BWBart van de Wiel
Bart van de Wiel
TSTon N. Schumacher
Ton N. Schumacher

8 April 2016 in Science
Verified
Journal Article
Closed access
PDF file
BVBenjamin Vernot
Benjamin Vernot
STSerena Tucci
Serena Tucci
JKJanet Kelso
Janet Kelso
JSJoshua G. Schraiber
Joshua G. Schraiber
AWAaron B. Wolf
Aaron B. Wolf
JAJoshua M. Akey
Joshua M. Akey
Denisovan DNA retained in Melanesians: Modern humans carry remnants of DNA from interbreeding events with archaic lineages, such as Neandertals. However, people from Oceania also retain genes from a second ancient lineage, the Denisovans. Vernot et al. surveyed archaic genomic sequences in a worldwide sample of modern humans, including 35 individuals from the Melanesian Islands. All non-African genomes surveyed contained Neandertal DNA, but a significant Denisovan component was found only in the Melanesians. Reconstruction of this genetic history suggests that Neandertals bred with modern humans multiple times, but Denosivans only once, in ancestors of modern-day Melanesians. Science , this issue p. 235

30 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Alexandre ReubenAlexandre Reuben
Alexandre Reuben
JZJiexin Zhang
Jiexin Zhang
SCShin-Heng Chiou
Shin-Heng Chiou
RGRachel M. Gittelman
Rachel M. Gittelman
JLJun Li
Jun Li
JZJianjun Zhang
Jianjun Zhang
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.

1 October 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ARAlexandre Reuben
Alexandre Reuben
RGRachel Gittelman
Rachel Gittelman
JGJianjun Gao
Jianjun Gao
JZJiexin Zhang
Jiexin Zhang
EYErik C. Yusko
Erik C. Yusko
JZJianjun Zhang
Jianjun Zhang
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were shown to alter tumor immunogenicity through T-cell responses. Here, we performed sequencing of the T-cell receptor (TCR) in 45 tumor regions from 11 localized lung adenocarcinomas and observed substantial intratumor differences in T-cell density and clonality with the majority of T-cell clones restricted to individual tumor regions. TCR ITH positively correlated with predicted neoantigen ITH, suggesting that spatial differences in the T-cell repertoire may be driven by distinct neoantigens in different tumor regions. Finally, a higher degree of TCR ITH was associated with an increased risk of postsurgical relapse and shorter disease-free survival, suggesting a potential clinical significance of T-cell repertoire heterogeneity. Significance: The present study provides insights into the ITH of the T-cell repertoire in localized lung adenocarcinomas and its potential biological and clinical impact. The results suggest that T-cell repertoire ITH may be tightly associated to genomic ITH and disease relapse. Cancer Discov; 7(10); 1088–97. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1047

1 December 2016 in Current Biology
Verified
Journal Article
Closed access
RGRachel M. Gittelman
Rachel M. Gittelman
JSJoshua G. Schraiber
Joshua G. Schraiber
BVBenjamin Vernot
Benjamin Vernot
CMCarmen Mikacenic
Carmen Mikacenic
MWMark M. Wurfel
Mark M. Wurfel
JAJoshua M. Akey
Joshua M. Akey

4 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TSThomas M. Snyder
Thomas M. Snyder
RGRachel M. Gittelman
Rachel M. Gittelman
MKMark Klinger
Mark Klinger
Damon MayDamon May
Damon May
EOEdward J. Osborne
Edward J. Osborne
HRHarlan S. Robins
Harlan S. Robins
T cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection. Here, we combined two high-throughput immune profiling methods to create a quantitative picture of the T-cell response to SARS-CoV-2. First, at the individual level, we deeply characterized 3 acutely infected and 58 recovered COVID-19 subjects by experimentally mapping their CD8 T-cell response through antigen stimulation to 545 Human Leukocyte Antigen (HLA) class I presented viral peptides (class II data in a forthcoming study). Then, at the population level, we performed T-cell repertoire sequencing on 1,815 samples (from 1,521 COVID-19 subjects) as well as 3,500 controls to identify shared “public” T-cell receptors (TCRs) associated with SARS-CoV-2 infection from both CD8 and CD4 T cells. Collectively, our data reveal that CD8 T-cell responses are often driven by a few immunodominant, HLA-restricted epitopes. As expected, the T-cell response to SARS-CoV-2 peaks about one to two weeks after infection and is detectable for at least several months after recovery. As an application of these data, we trained a classifier to diagnose SARSCoV-2 infection based solely on TCR sequencing from blood samples, and observed, at 99.8% specificity, high early sensitivity soon after diagnosis (Day 3–7 = 85.1% [95% CI = 79.9-89.7]; Day 8–14 = 94.8% [90.7-98.4]) as well as lasting sensitivity after recovery (Day 29+/convalescent = 95.4% [92.1-98.3]). These results demonstrate an approach to reliably assess the adaptive immune response both soon after viral antigenic exposure (before antibodies are typically detectable) as well as at later time points. This blood-based molecular approach to characterizing the cellular immune response has applications in clinical diagnostics as well as in vaccine development and monitoring.